GSK Enters Agreement to Acquire Aiolos Bio

SAN FRANCISCO & LONDON–(BUSINESS WIRE)–GSK plc (LSE/NYSE: GSK) and Aiolos Bio, Inc. (Aiolos) today announced that they have entered into an agreement under which GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with certain respiratory and inflammatory conditions, for a $1…
Click here to view original post